6 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
and Development (R&D) expenses for the quarter ended March 31, 2024 were $30.8 million, compared to $12.3 million for the quarter ended March 31, 2023. The increase … in R&D expenses was primarily due to increases of $16.8 million in preclinical and clinical costs, $3.7 million in clinical supply, manufacturing
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
clinical studies, as well as support corporate operations, into 2026.
Research and Development (R&D) expenses were $70.4 million for the year ended … December 31, 2023, compared to $26.3 million for the year ended December 31, 2022. R&D expenses for the quarter ended December 31, 2023 were $23.7
8-K
EX-99
MLYS
Mineralys Therapeutics Inc
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
of the company and pivoting its R&D direction. Previously, Dr. Kim served on the Global Oncology Business Development and Licensing group at Hoffmann-La Roche
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
, as well as support corporate operations, through mid-2025.
Research and Development (R&D) expenses were $22.5 million for the quarter ended September … 30, 2023, compared to $6.1 million for the quarter ended September 30, 2022. The increase in R&D expenses was primarily due to increases of $12.4
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
and Development (R&D) expenses were $11.9 million for the quarter ended June 30, 2023, compared to $5.6 million for the quarter ended June 30, 2022 … . The increase in R&D expenses was primarily due to increases of $4.0 million in preclinical and clinical costs, driven by the initiation of the lorundrostat
8-K
EX-99.1
i1l1nnh
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
- Prev
- 1
- Next